Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025AdolescentsOpen Access

Evidence for Cannabidiol as a Medication for the Treatment of Neurological, Psychiatric, Behavioral and Substance Use Disorders in Adolescents

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJennifer A. RossWRWilliam RiccardelliJRJames Robitaille

Discussion

Loading...

Member takes

Overview

This review summarizes cannabidiol’s effects on epilepsy and mental health in adolescents, indicating regulatory concerns.

Key Points

  • Cannabidiol may have anti-anxiety and anti-convulsant properties, but its long-term safety in adolescents remains unclear.
  • Current FDA approval for CBD is limited to epilepsy treatment; other indications lack substantial evidence.
  • Legislative changes have increased CBD availability, raising concerns about unregulated products and their safety.
  • The potential impact on brain development during adolescence highlights the need for caution in CBD use.

Cite This Study

Ross et al. (2025) studied this question.

synapsesocial.com/papers/68dd953bfe798ba2fc4998f5https://doi.org/10.3390/adolescents5040054
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cannabidiol and positive effects on object recognition memory in an in vivo model of Fragile X Syndrome: Obligatory role of hippocampal GPR55 receptors2024 · 10 citations
  2. 2Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome2023 · 18 citations
  3. 3Updates on Sturge-Weber Syndrome2022 · 95 citations
  4. 4The efficacy of cannabidiol for seizures reduction in pharmacoresistant epilepsy: a systematic review and meta-analysis2025 · 6 citations
  5. 5<p>CBD Effects on TRPV1 Signaling Pathways in Cultured DRG Neurons</p>2020 · 82 citations